Opioid plasma concentration during switching from morphine to methadone: preliminary data

Area of Science:

• Oncology
• Pharmacology
• Pain Management

Background:

• Opioid switching is a common strategy for cancer patients with inadequate pain control or adverse effects.
• Limited data exist on the pharmacokinetic changes of opioids and their metabolites during switching and their correlation with clinical outcomes.

Purpose of the Study:

• To investigate the plasmatic changes of opioids and their metabolites during oral morphine to oral methadone switching in cancer patients.
• To assess the relationship between these pharmacokinetic changes and clinical improvements in pain and adverse effects.

Main Methods:

• A prospective study involving 10 cancer patients experiencing uncontrolled pain or severe adverse effects on oral morphine.
• Patients were switched to oral methadone using a 5:1 ratio, with additional methadone doses as needed.
• Blood samples were collected for four days (pre-switch and days 1-3 post-switch) to measure opioid and metabolite levels.
• Pain intensity and adverse effects were assessed daily to calculate a switching score.

Main Results:

• Significant improvements in pain intensity and adverse effects were observed within 1-2 days post-switching.
• Plasma concentrations of morphine and its metabolites (M6G, M3G) decreased significantly, nearly disappearing within three days.
• Oral methadone achieved stable plasma concentrations within 1-2 days.
• Methadone dosage adjustments were minimal and tended to decrease over time.

Conclusions:

• Rapid cessation of morphine and initiation of a methadone priming dose is recommended for effective opioid switching.
• This approach facilitates rapid clearance of morphine and its metabolites, except in patients with renal impairment.
• Observed pharmacokinetic changes correlate with clinical improvements in analgesia and reduced adverse effects.